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 Disorders/differences of sex development (DSD) are 
generally rare conditions requiring specialized care by 
multidisciplinary teams. Recently, the European Union 
has launched an initiative to establish European Refer-
ence Networks (ERNs) for rare disorders. The aim of 
these networks is to ensure equal access to high-quality 
care for all those affected by a rare condition across Eu-
rope, both children and adults. The largest network that 
has successfully applied and has recently become opera-
tional is the ERN Rare Endocrine Disorders (Endo-ERN). 
Within this ERN, several main thematic groups have been 
formed, one of which is “Sexual Development & Matura-
tion,” which includes DSD.
 The work-plan of the Endo-ERN has defined several 
work packages, one of which is “Diagnostics & Labora-
tory Analysis.” Among the tasks of this work package are 
the creation of an EU network of specialized accredited 
laboratories that offer diagnostic tests for endocrine dis-
eases and the development of a web-based external qual-
ity control application. Concerning laboratory determi-
nations relevant to DSD, this laboratory network within 
Endo-ERN can build on the work done within the COST 
Action “DSDnet” by the working group “Harmonization 
of Laboratory Assessment” (www.dsdnet.eu). This work-
ing group has recently published a position paper on ste-
roid hormone analysis in diagnosis and treatment of DSD 
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 Abstract 
 The aim of the European Reference Network for Rare Endo-
crine Disorders (Endo-ERN) is to ensure equal access to high-
quality care for all those affected by a rare endocrine con-
dition across Europe, such as a disorder/difference of sex 
development (DSD), both for children and adults. Although 
differences in resources, health care systems, and health in-
surances between the European countries are challenging 
and require political action, a European laboratory network 
within Endo-ERN could improve the diagnostic process in in-
dividuals with DSD, building on the work done by previous 
European collaborations such as the COST action DSDnet. In 
close collaboration, clinicians and laboratory specialists must 
make every effort to standardize diagnostic protocols, 
achieve necessary harmonization of various laboratory tests, 
e.g., the hCG stimulation test, and implement an external 
quality control system. This should ideally result in compa-
rable quality across the network centers allowing the sharing 
of reference values. This would not only improve patient care 
but also greatly facilitate research.  © 2018 The Author(s)
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[Kulle et al., 2017] and has established a pilot external 
quality assurance (EQA) program for serum dihydrotes-
tosterone (DHT) [Greaves et al., 2017].
 Laboratory investigations play a key role in the diag-
nostic workflow in individuals with suspected DSD 
[Hughes et al., 2006]. Establishing the right diagnosis is 
essential to counsel on prognosis, appropriate therapy, 
and necessary screening for associated comorbidities, 
and, especially in neonates, on the sex of rearing. In the 
last decade, next-generation sequencing has become 
widely available, and consequently the introduction of 
gene panels has made it possible to analyze a large num-
ber of genes in a short period of time. Besides genetic 
testing, endocrine investigations are still needed. Gene 
mutations can lead to a highly variable phenotype. For 
example,  NR5A1 mutations in 46,XY individuals can 
result in phenotypes ranging from complete gonadal 
dysgenesis to male infertility [Achermann et al., 1999; 
Bashamboo et al., 2010]. Thus, hormone measurements 
remain essential for the assessment of gonadal function. 
Furthermore, when unclassified variants are found with 
genetic testing, hormone measurements can also be 
helpful to assess the likelihood that these variants are 
pathogenic. For example, if variants are found in the 
gene encoding 17-β-HSD type 3, a high androstenedi-
one/testosterone ratio in the hCG test supports patho-
genicity. In addition, measurement of various hormones 
is helpful in monitoring of spontaneous pubertal devel-
opment and of hormonal therapy [Bhasin et al., 2010; 
Speiser et al., 2010]. Ideally, all tests considered essential 
for diagnostic purposes and for monitoring of therapy 
should be available and of sufficient quality across Eu-
rope.
 Selection of Hormone Measurements Essential for 
Diagnosis and Management of DSD 
 Consensus amongst clinicians is required on what 
tests are considered essential in the diagnosis and man-
agement of DSD. The consensus statement from 2006 
suggests 17-α-hydroxyprogesterone (17OHP), testoster-
one, gonadotropins, anti-müllerian hormone (AMH), se-
rum electrolytes, and urine analysis as the set of initial 
investigations when DSD is suspected, which may be fol-
lowed by further investigations such as an hCG test, 
ACTH test, and urinary steroid profile. In 2011, the Soci-
ety for Endocrinology UK has provided guidance on the 
initial investigation of a child with DSD which has been 
updated in 2015 [Ahmed et al., 2011, 2016]. Their first 
line of recommended endocrine laboratory investiga-
tions includes 17OHP to exclude congenital adrenal hy-
perplasia (CAH). If CAH is suspected, androstenedione, 
testosterone, possibly renin, and a urinary steroid profile 
can be measured. In children with a karyotype other than 
46,XX, measurement of AMH and an hCG test is sug-
gested to investigate testicular development and andro-
gen synthesis. At a minimum, testosterone, androstene-
dione and DHT should be measured in the hCG test 
[Ahmed et al., 2016]. If testosterone does not rise suffi-
ciently after hCG stimulation, a short ACTH stimulation 
test should be considered [Ahmed et al., 2016].
 A survey among various European DSD clinics has 
shown considerable variation in the choice of diagnostic 
tests. This may partly be due to nonavailability of tests in 
certain clinics but might also be related to different pro-
tocols being used to establish a diagnosis. It would be 
helpful to develop a European guideline describing the 
diagnostic work-up of DSD. Depending on the differen-
tial diagnosis and age of the child, a different set of tests 
may be needed [Hughes et al., 2006]. A recommended 
diagnostic workflow should be described for several fair-
ly common scenarios such as the neonate with ambigu-
ous genitalia or the adolescent presenting with absent or 
abnormal pubertal development [Ahmed et al., 2011, 
2016].
 That steroid hormone measurements play an essential 
role in the monitoring of therapy is clear from various 
guidelines. Measurement of 17OHP, androstenedione, 
and testosterone is recommended to assess the adequacy 
of glucocorticoid therapy in CAH [Speiser et al., 2010], 
and measurement of testosterone levels is recommended 
in men receiving testosterone therapy because of andro-
gen deficiency [Bhasin et al., 2010].
 The availability of a predefined diagnostic panel con-
sidered essential for standardized evaluation and follow-
up of individuals with DSD should be a requirement for 
all DSD expert centers just as the presence of a multidis-
ciplinary DSD team [Ahmed et al., 2016].
 Performance of Hormone Measurements 
 The quality assessment of the endocrine tests, depen-
dent on the right pre-analytical, analytical, and post-ana-
lytical conditions, is considered essential for diagnosis 
and management of DSD and should be regularly moni-
tored by an (inter)national EQA program.
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 Timing of Laboratory Investigations and Test 
Protocols 
 During the diagnostic workflow of a child with DSD, 
optimal timing of hormone measurements is important 
to produce reliable and useful results, and it may be nec-
essary to repeat investigations at a later age [Ahmed et al., 
2016]. While the measurement of adrenal steroids to di-
agnose CAH may be less reliable during the first 36 h of 
life, a urinary steroid profile cannot be used to assess the 
likelihood of 5α-reductase deficiency before 3 months of 
age [Ahmed et al., 2016]. The hypothalamus-pituitary-
gonadal (HPG) axis is active prenatally, during minipu-
berty, with peak testosterone levels at 1–3 months of age 
in boys [Kuiri-Hanninen et al., 2014] and then from pu-
berty onwards. In the periods where this axis is quiescent, 
basal steroid measurements are uninformative so that a 
stimulation test is needed.
 The hCG test is commonly used in the initial evalua-
tion of a child with 46,XY DSD, but this test is not stan-
dardized. Protocols range from a single injection to 3 in-
jections on consecutive days, to 6 injections every other 
day, to more extended stimulation for up to 3 weeks. Fur-
thermore, there is a range in dosing from 500 to 1500 IU 
or a weight or body surface area based dose. Blood sam-
ples for steroid measurements are drawn 24–72 h after the 
(last) injection [Kolon and Miller, 2001; Feyaerts et al., 
2002; Ahmed et al., 2011]. There is a need for standardiza-
tion of the test protocol to ensure that test results are com-
parable across different European countries. The proto-
cols may need to be different for various age groups as the 
gonad is more responsive to hCG during periods when 
the HPG axis is active, i.e., the first half year of life (mini-
puberty) [Kuiri-Hanninen et al., 2014] and puberty, than 
in childhood when the HPG axis is quiescent [Bhowmick 
and Gidvani, 2000].
 Laboratory Analysis of Steroids 
 Accurate measurements of steroid concentrations are 
critical to support clinical decisions. However, in neo-
nates, measurement of steroids may be problematic. Be-
sides quite different concentrations of many steroids in 
neonates’ serum compared to those in older children, 
neonatal serum contains a different mix of steroids pro-
duced by the fetal adrenal zone that interferes with 
17OHP, androstenedione, and testosterone measure-
ment [Wong et al., 1992; Wudy et al., 1995]. In addition, 
interfering molecules can also be drugs or structurally re-
lated endogenous compounds, e.g., DHEAS interferes 
with testosterone [Warner et al., 2006; Middle, 2007] and 
methylprednisolone with cortisol immunoassays. Fur-
thermore, nonspecific cross-reactivity leads to falsely el-
evated steroid concentrations.
 To improve sensitivity and specificity, an increasing 
number of clinical laboratories use LC-MS/MS (tandem 
liquid chromatography-tandem mass spectrometry) 
methods for steroid hormone measurements. Further-
more, the LC-MS/MS method facilitates steroid profiling 
which is very informative in distinguishing almost all ste-
roid related disorders. Although costs and required tech-
nical skills have limited the adoption of this state-of-the-
art technology in all regions of Europe, this method for 
steroid analysis is becoming increasingly available for 
routine use. Of the hormones essential for the diagnosis 
and management of DSD, reference LC-MS/MS method 
procedures have only been developed for cortisol and tes-
tosterone. These methods have been deployed to produce 
higher-order certified reference materials which are used 
to calibrate commercial immunoassays generally used in 
routine clinical laboratories. Still, the problem with the 
standardization of both automated immunoassays and 
radio- or enzyme-linked immunoassays for steroids re-
mains.
 Laboratories should aim to participate in activities of 
peer comparison such as a sample exchange or preferably 
when available subscribe to an EQA program to improve 
quality and comparability between laboratory tests. The 
availability of certified reference materials, reference 
methods, reference laboratories, and reference intervals 
and decision limits will improve the standardization of 
steroid analysis. In addition to standardization, reference 
intervals and decision limits are of tremendous value for 
the correct interpretation of steroid concentrations in 
premature and term neonates. However, reference inter-
vals are not widely available, and in contrast to earlier 
anticipation these are mostly dependent on individual 
specific laboratory settings determined by sample work-
up and/or instrumentation. It has become difficult to re-
cruit healthy children, especially neonates or premature 
infants, to establish normative reference data from a con-
trol cohort. This is mainly the result of ethical concerns 
and prevents the implementation of accurate age-, Tan-
ner stage- and sex-specific reference intervals. A broad 
European initiative is needed to make good reference val-
ues for steroids available to clinical laboratories.
 To further reduce the variability and interferences in 
steroid measurements, which can affect patient diagnosis 
and management, initiatives to support harmonization 
have been embraced globally. The working group “Har-
monization of Laboratory Assessment” of the COST Ac-
tion “DSDnet” has already started to work on an EQA 
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program for 17OHP [Kulle et al., 2017]. Recently, a first 
EQA program for the harmonization of serum dihy-
drotestosterone measurement has been launched 
[Greaves et al., 2017]. The CDC established the Hormone 
Standardization Program to improve the accuracy of tes-
tosterone assays (https://www.cdc.gov/labstandards/pdf/
hs/Testosterone_Protocol.pdf). An important aspect of 
harmonized reference intervals is the development of cri-
teria for a laboratory to use a common reference interval.
 Current guidelines use absolute decision limits, such 
as aiming for a serum testosterone concentration of 14.1–
24.5 nmol/L midway between injections in men being 
treated with testosterone [Bhasin et al., 2010], or rejecting 
the diagnosis CAH when ACTH-stimulated 17OHP is 
<50 nmol/L [Speiser et al., 2010] although cut-offs may 
differ depending on the assay. International harmoniza-
tion of assays and the use of common reference intervals 
would allow clinicians to use cut-offs from guidelines 
with confidence that the decision limits are applicable to 
their local situation. Ensuring that hormone measure-
ments are directly comparable across countries would not 
only be of clinical value but would also greatly facilitate 
international research that relies on steroid measure-
ments. These benefits justify investing in international 
rather than national harmonization.
 Availability of Essential Tests 
 Not all tests that are considered necessary for the diag-
nostic evaluation and monitoring of treatment in indi-
viduals with DSD are currently locally available at all cen-
ters delivering specialist care for individuals with DSD as 
was shown in a recent survey amongst European and 
non-European centers [Kyriakou et al., 2016]. Essential 
 diagnostic hormone tests that were frequently reported to 
be unavailable were AMH (21%) and DHT (19%). Al-
though samples can be sent to a laboratory elsewhere, this 
will result in longer turnaround times. If a test was not 
available at a local accredited laboratory, clinicians were 
less likely to routinely perform this test. Most clinicians 
to whom these tests were unavailable indicated they 
would consider performing the test if it was available 
[Kyriakou et al., 2016]. For optimal quality of care the 
panel of essential diagnostic tests should be available at 
every DSD expert center.
 An inventory of laboratories eligible for the ERN accred-
itation will be made in the first year of the Endo-ERN as task 
of the work-plan “Diagnostics & Laboratory Analysis.” If 
DSD centers are identified that lack appropriate laboratory 
facilities, an effort will have to be made to help establish 
these facilities or else referral pathways to other DSD cen-
ters will have to be created to ensure that individuals 
throughout Europe have access to high-quality diagnostics 
and consequently high-quality care. Another barrier may 
lie in the reimbursement of laboratory in vestigations. It 
may be challenging to solve problems of availability and re-
imbursement of laboratory diagnostics given the differenc-
es in health care systems and health insurance between Eu-
ropean countries, and this requires political action.
 Novel Tests 
 In addition to a defined set of laboratory investigations 
considered essential to the diagnostic process and moni-
toring of treatment in individuals with (suspected) DSD, 
other (novel) tests may be helpful in specific cases. For 
example, measurement of autoantibodies against steroid-
producing cells may help to identify autoimmunity as a 
cause of ovarian failure [La Marca et al., 2010]. A 24-h 
urinary steroid profile may help distinguish between a 
rare adrenal enzyme deficiency such as apparent corti-
sone reductase deficiency and the more common 21-hy-
droxylase deficiency [Biason-Lauber et al., 2000]. Al-
though currently mainly used in research, future clinical 
applications may be identified for insulin-like factor 3 
(INSL3), a peptide hormone produced by Leydig cells 
which is thought to reflect their differentiation status and 
function [Ferlin et al., 2006]. Another example might be 
a common investigation such as measurement of steroids 
but in a different matrix, such as in scalp hair. Steroid lev-
els measured using this noninvasive method reflect aver-
age serum levels over a longer period of time. Recently, 
measurement of androstenedione and 17OHP in scalp 
hair was suggested for monitoring treatment of CAH 
[Noppe et al., 2016].
 Some novel tests are currently research-based but may 
possibly be useful for diagnosis or management in the fu-
ture. An example is the assay that uses DHT-dependent 
transcriptional induction of the androgen receptor (AR) 
target gene apolipoprotein D in genital skin fibroblasts to 
assess androgen action [Hornig et al., 2016]. This assay is 
able to discriminate between individuals with androgen 
insensitivity caused by an  AR mutation and unaffected 
individuals. In a group of individuals with 46,XY DSD in 
whom androgen insensitivity was suspected but no  AR 
mutation was identified, the assay indicated disrupted an-
drogen signaling in 37% [Hornig et al., 2016].This assay 
may be clinically useful for diagnostic as well as prognos-
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tic purposes, for example to predict the response to an-
drogen treatment [Hornig et al., 2016].
 In order to improve access to such tests, the ERN could 
create a web-based searchable database of available tests 
and which centers provide them. Such databases already 
exist for genetic tests on the orphanet website (www.or-
pha.net). Insight in who offers what tests will facilitate 
health care providers looking for specific tests outside 
their own center. This should also help to coordinate the 
development of (novel) tests. To efficiently make use of 
limited resources, work on novel tests should ideally be a 
joint action of the various DSD centers.
 In conclusion, collaboration of clinicians and labora-
tory specialists is required to achieve harmonization of 
various laboratory tests, including standardization of 
protocols. There is a demand for European investments 
to establish a network of highly specialized endocrine ref-
erence laboratories and to create a web-based searchable 
database of available tests to achieve a Pan-European 
landscape ensuring access to optimal laboratory assess-
ment for DSD. The establishment of this laboratory net-
work should be embedded in a network of internation-
ally accredited DSD expert centers.
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